Infinity Pharmaceuticals, Inc. (INFIQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Infinity Pharmaceuticals, Inc. (INFIQ) trades at $0.00 with AI Score 62/100 (Grade B+). Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Market cap: $9,076, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for INFIQ: INFIQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INFIQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
INFIQ: 2/4 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Infinity Pharmaceuticals, Inc. (INFIQ) Healthcare & Pipeline Overview
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to creating novel cancer treatments, particularly through its lead candidate eganelisib, while strategically collaborating with industry partners to enhance its research and development capabilities.
What Is the Investment Thesis for INFIQ?
Infinity Pharmaceuticals, Inc. is currently positioned in a challenging financial landscape following its Chapter 11 liquidation approval. The company's lead product candidate, eganelisib, remains in clinical development, with potential catalysts tied to trial outcomes in the oncology space. The strategic alliances with firms like Verastem and Bristol Myers Squibb provide a framework for future collaborations, which could enhance product development and commercialization efforts. However, the absence of revenue generation and the high beta of 8.79 indicate substantial volatility and risk. Investors should closely monitor trial results and any developments regarding potential partnerships or licensing agreements that could provide liquidity and operational stability in the coming years.
Based on FMP financials and quantitative analysis
INFIQ Key Highlights
- Market Cap: $0.00B, indicating a significant downturn in financial health.
- Beta: 8.79, reflecting high volatility compared to the market.
- Employees: 30, showcasing a lean operational structure amidst financial restructuring.
- No dividend yield, aligning with the company's focus on growth and development rather than returning capital to shareholders.
- Current status involves Chapter 11 liquidation, impacting future operational capabilities.
Who Are INFIQ's Competitors?
INFIQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $528.88 | +0.16% | $134.23B | 99 |
| BMY Bristol-Myers Squibb Company | $56.73 | -2.40% | $115.86B | 88 |
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INFIQ's Key Strengths?
- Innovative product pipeline with a focus on immuno-oncology.
- Established strategic alliances with leading pharmaceutical companies.
- Experienced management team with expertise in drug development.
What Are INFIQ's Weaknesses?
- Current financial instability due to Chapter 11 liquidation.
- Limited revenue generation with no current products on the market.
- High operational risk associated with clinical trial outcomes.
What Could Drive INFIQ Stock Higher?
- Results from Phase 2 clinical trials for eganelisib, which could influence market perception and future funding.
- Strategic partnerships that may lead to collaborative developments and potential revenue opportunities.
- Monitoring the outcomes of the Chapter 11 liquidation process and its impact on operational capabilities.
What Are the Key Risks for INFIQ?
- The ongoing financial instability due to Chapter 11 liquidation may hinder operational effectiveness.
- High operational risk associated with the success of clinical trials, which are critical for future product viability.
- Intense competition in the oncology market could limit market share and profitability.
What Are the Growth Opportunities for INFIQ?
- Growth opportunity 1: Infinity's lead candidate, eganelisib, is currently in Phase 2 trials for metastatic triple negative breast cancer, a market expected to reach $25 billion by 2026. Successful trial outcomes could position Infinity favorably within this lucrative segment, especially as the demand for innovative cancer therapies continues to rise.
- Growth opportunity 2: The collaboration with Verastem, Inc. for duvelisib presents a potential revenue stream through co-development and commercialization efforts. The global market for duvelisib and similar drugs is projected to expand significantly, driven by increased adoption in oncology treatments, providing Infinity with a strategic advantage.
- Growth opportunity 3: Infinity's partnerships with major firms like Bristol Myers Squibb and Roche could lead to enhanced research capabilities and shared resources. These collaborations may facilitate faster development timelines and access to broader patient populations, which are critical for successful drug commercialization.
- Growth opportunity 4: The ongoing development of IPI-926, a hedgehog inhibitor, represents another avenue for growth. The hedgehog signaling pathway is implicated in various cancers, and successful development could open up additional markets, particularly in solid tumors.
- Growth opportunity 5: The increasing focus on immuno-oncology therapies in the healthcare sector aligns with Infinity's strategic direction. As the market for immunotherapies is expected to grow at a CAGR of over 15%, Infinity's innovative approaches could capture a significant share if clinical trials yield positive results.
What Opportunities Does INFIQ Have?
- Growing market for cancer therapeutics, particularly immuno-oncology.
- Potential for successful partnerships to enhance drug development.
- Expansion into new therapeutic areas with innovative product candidates.
What Threats Does INFIQ Face?
- Intense competition in the biotechnology and oncology sectors.
- Regulatory hurdles that could delay product approvals.
- Market volatility impacting investor confidence and funding.
What Are INFIQ's Competitive Advantages?
- Strong focus on immuno-oncology, a rapidly growing field in cancer treatment.
- Strategic partnerships with established pharmaceutical companies enhance credibility and resources.
- Innovative product candidates with unique mechanisms of action set the company apart from competitors.
- Experienced leadership team with a track record in drug development and commercialization.
What Does INFIQ Do?
Founded in 1995 and headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative medicines for cancer treatment. The company has carved a niche in the biotechnology sector with its focus on immuno-oncology, particularly through its lead product candidate, eganelisib (IPI-549). This orally administered drug is currently in Phase 2 clinical trials targeting metastatic triple negative breast cancer and urothelial cancer, as well as in Phase 1/1b trials for solid tumors. Infinity has established strategic alliances with several companies, including Intellikine, Inc. for the development of PI3K-targeted therapies, Verastem, Inc. for the commercialization of duvelisib, and PellePharm, Inc. for its hedgehog inhibitor program, IPI-926. These collaborations enhance Infinity's research capabilities and market reach. However, the company faced significant financial challenges, culminating in a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on September 29, 2023. The reorganization plan was later approved as a Chapter 11 liquidation on March 7, 2024, impacting its operations and future prospects.
What Products and Services Does INFIQ Offer?
- Develop novel medicines specifically targeting cancer treatment.
- Focus on immuno-oncology therapies to enhance patient outcomes.
- Conduct clinical trials for lead product candidates, including eganelisib.
- Establish strategic alliances with other biopharmaceutical companies to expand research capabilities.
- Engage in the commercialization of innovative cancer therapies.
- Navigate regulatory processes for drug approval and market entry.
How Does INFIQ Make Money?
- Generate revenue through partnerships and collaborations in drug development.
- Focus on clinical trial successes to drive future product sales.
- Leverage strategic alliances to share development costs and risks.
- Seek licensing agreements for drug commercialization in various markets.
- Utilize research grants and funding for ongoing clinical projects.
What Industry Does INFIQ Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in oncology. The global cancer therapeutics market is projected to grow substantially, driven by increasing cancer incidence and advancements in personalized medicine. Companies like Infinity Pharmaceuticals, which are focused on immuno-oncology, are positioned to benefit from these trends. However, the competitive landscape is intense, with numerous players vying for market share in developing effective cancer treatments, highlighting the importance of successful clinical trial outcomes and strategic partnerships.
Who Are INFIQ's Key Customers?
- Healthcare providers and hospitals seeking innovative cancer treatments.
- Pharmaceutical companies interested in collaboration for drug development.
- Investors looking for opportunities in the biotechnology sector.
- Patients requiring advanced cancer therapies.
- Regulatory bodies for drug approval and compliance.
How Infinity Pharmaceuticals, Inc. Is Valued
Infinity Pharmaceuticals, Inc. carries a market capitalization of 9K, placing it in the micro-cap category. Relative to its peer group, INFIQ's quantitative score of 62/100 is below the peer average of 91/100.
Company Profile
Infinity Pharmaceuticals, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Vishal Mehta. INFIQ has traded publicly since 2000.
FY2026 estForward Outlook
Wall Street analysts project Infinity Pharmaceuticals, Inc. revenue of about $18.0M for fiscal 2026, with EPS near $-0.13.
INFIQ Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in the potential of their pipeline.
- Community sentiment has shifted positively as recent trial results have sparked discussions about potential breakthroughs in treatment.
- The company’s focus on innovative cancer therapies aligns with increasing market demand for targeted treatments, attracting interest from investors.
- Positive media coverage has highlighted Infinity's advancements, boosting visibility and potentially attracting new investors.
Bear Case
- Concerns over the company's cash runway have surfaced, leading some investors to question its ability to sustain operations without additional funding.
- Recent market sentiment indicates skepticism about the long timelines associated with clinical trials, which could delay revenue generation.
- Bearish community discussions have emerged regarding competitive pressures from larger pharmaceutical companies, which may overshadow Infinity's innovations.
- Recent volatility in biotech stocks has led to increased caution among investors, impacting overall sentiment towards smaller firms like Infinity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
INFIQ Latest News
No recent news available for INFIQ.
INFIQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INFIQ.
Price Targets
Wall Street price target analysis for INFIQ.
INFIQ MoonshotScore
What does this score mean?
The MoonshotScore rates INFIQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lawrence E. Bloch
CEO
Lawrence E. Bloch has extensive experience in the biopharmaceutical industry, having held various leadership roles throughout his career. He has a strong background in drug development and commercialization, with a focus on oncology. His educational credentials and experience in managing clinical-stage companies position him well to lead Infinity Pharmaceuticals through its current challenges.
Track Record: Under Lawrence's leadership, Infinity has pursued strategic collaborations with major pharmaceutical companies, enhancing its research capabilities and market reach. His focus on innovative cancer therapies has guided the company's product development efforts.
INFIQ OTC Market Information
The OTC Other tier includes companies that do not meet the listing requirements for the major exchanges like NYSE or NASDAQ. These companies often have lower visibility and liquidity, making them riskier investments. However, they can provide opportunities for investors willing to take on additional risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- High volatility associated with OTC stocks, particularly in the biotechnology sector.
- Limited financial transparency due to bankruptcy proceedings.
- Potential for significant losses if clinical trials do not yield positive results.
- Verify the status of ongoing clinical trials and their outcomes.
- Assess the financial health and restructuring plans post-bankruptcy.
- Review partnerships and collaborations for potential revenue streams.
- Monitor industry trends in oncology and immuno-oncology.
- Evaluate the management team's experience and track record.
- Established partnerships with reputable pharmaceutical companies.
- Presence in clinical trials, indicating ongoing research and development.
- Historical focus on innovative cancer therapies, aligning with market needs.
What Investors Ask About Infinity Pharmaceuticals, Inc. (INFIQ) — Healthcare
What does Infinity Pharmaceuticals, Inc. do?
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative cancer therapies. The company's lead product candidate, eganelisib, is in clinical trials for treating various cancers, including metastatic triple negative breast cancer. Through strategic partnerships, Infinity aims to enhance its research capabilities and bring novel treatments to market.
What are the main risks for INFIQ?
Infinity Pharmaceuticals, Inc. faces several risks, including financial instability due to its Chapter 11 liquidation process, which may impede its operational capabilities. Additionally, there is a high operational risk tied to the success of clinical trials, which are critical for the company's future. The competitive landscape in the oncology market poses another threat, as numerous companies are vying for market share with similar innovative therapies.
How does Infinity Pharmaceuticals, Inc. manage patent expiration risks?
Infinity Pharmaceuticals, Inc. has strategies in place to manage patent expiration risks, including ongoing research and development of new compounds that could replace or supplement existing products. The company also focuses on securing partnerships that may provide additional intellectual property protections and enhance its portfolio. By continuously innovating and adapting to market changes, Infinity aims to mitigate the impact of patent expirations on its revenue streams.
What are the key factors to evaluate for INFIQ?
Infinity Pharmaceuticals, Inc. (INFIQ) holds an AI score of 62/100 (moderate). Not financial advice.
How frequently does INFIQ data refresh on this page?
INFIQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven INFIQ's recent stock price performance?
Infinity Pharmaceuticals, Inc. (INFIQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline with a focus on immuno-oncology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INFIQ overvalued or undervalued right now?
Valuing Infinity Pharmaceuticals, Inc. (INFIQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying INFIQ?
Before investing in Infinity Pharmaceuticals, Inc. (INFIQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The company is currently undergoing Chapter 11 liquidation, which significantly impacts its operational status and financial reporting.